Cargando…

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal

Drug-induced liver injury (DILI) with nintedanib has emerged as an adverse event of special interest in premarketing clinical trials. We characterized DILI with nintedanib in the real world and explored the underlying pharmacological basis. First, we assessed serious hepatic events reported to the F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raschi, Emanuel, Fusaroli, Michele, Gatti, Milo, Caraceni, Paolo, Poluzzi, Elisabetta, De Ponti, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146184/ https://www.ncbi.nlm.nih.gov/pubmed/35631471 http://dx.doi.org/10.3390/ph15050645

Ejemplares similares

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
por: Gatti, Milo, et al.
Publicado: (2019)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Drug-induced liver injury: Towards early prediction and risk stratification
por: Raschi, Emanuel, et al.
Publicado: (2017)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
por: Poluzzi, Elisabetta, et al.
Publicado: (2014)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
por: Girardi, Anna, et al.
Publicado: (2014)

Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
por: Girardi, Anna, et al.
Publicado: (2015)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
por: Fusaroli, Michele, et al.
Publicado: (2023)

Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta‐analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database
por: Swart, Floor, et al.
Publicado: (2020)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
por: Berardi, Lorenzo, et al.
Publicado: (2019)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
por: Noguchi, Yoshihiro, et al.
Publicado: (2023)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pq4fejea8dk532rvtpm1q5b86h